Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 21, 2012; 18(19): 2371-2376
Published online May 21, 2012. doi: 10.3748/wjg.v18.i19.2371
Table 1 Clinical characteristics of the study population (mean ± SD)
VariablesPTPE group (n = 9)PVL group (n = 4)P value
Age (yr)69.7 ± 3.258.9 ± 2.90.0002
Sex (male:female)7:23:1
Background
(HCV:HBV:NBNC)1:1:71:1:2
Albumin (g/dL)3.9 ± 0.44.0 ± 0.40.61
Bilirubin (mg/dL)0.9 ± 0.41.2 ± 0.70.35
AST (IU/L)30.6 ± 12.232.3 ± 8.50.47
ALT (IU/L)35.9 ± 29.129.3 ± 15.60.92
WBC (/mm3)6744 ± 31095228 ± 19730.41
PLT (× 104/mL)22.1 ± 11.019.3 ± 9.90.76
PT (%)84.1 ± 10.584.5 ± 12.20.86
ICG 15 (%)10.7 ± 7.417.5 ± 13.20.43
Child pugh (A:B:C)7:2:03:1:0
Table 2 Right hepatic lobe atrophy rate 1 mo after percutaneous transhepatic portal vein embolization or portal vein ligation (mean ± SD)
VariablesPTPE group (n = 9)PVL group (n = 4)P value
Preoperative RHL volume (mL)804.9 ± 181.1813.3 ± 129.70.83
Preoperative RHL volume rate (%)68.9 ± 2.869.2 ± 4.20.94
Postoperative RHL volume (mL)638.4 ± 153.6749.8 ± 121.90.14
Postoperative RHL volume rate (%)54.6 ± 4.263.7 ± 3.90.0056
RHL atrophy rate 1 mo postoperation (%)14.3 ± 2.35.4 ± 1.60.0061